Conduct a comparative analysis of different vaccine introduced for Covid 19.
Answers
Answer:
Pfizer-BioNTech
Pfizer-BioNTech was the first COVID-19 vaccine to receive full Food and Drug Administration (FDA) approval for people ages 16 and older in August 2021. It was also the first COVID-19 vaccine to receive FDA Emergency Use Authorization (EUA) back in December 2020, after the company reported its vaccine was highly effective at preventing symptomatic disease. This is a messenger RNA (mRNA) vaccine, which uses a relatively new technology. It must be stored in freezer-level temperatures, which can make it more difficult to distribute than some other vaccines.
Moderna
Moderna’s vaccine was authorized for emergency use in the U.S. in December 2020, about a week after the Pfizer vaccine. Moderna uses the same mRNA technology as Pfizer and has a similarly high efficacy at preventing symptomatic disease. It also needs to be stored in freezer-level temperatures. In mid-August, the FDA approved a third dose of the Moderna vaccine for certain immuno-compromised individuals.
Oxford-AstraZeneca is currently studying the efficacy of a booster shoot.
Novavax
This vaccine has been shown to be highly effective in clinical trials. The Novavax vaccine is a protein adjuvant. It is simpler to make than some of the other vaccines and can be stored in a refrigerator, making it easier to distribute. Novovax has studied its vaccine in combination with the influenza vaccine with positive results.